

## Livmarli® (maralixibat) - Expanded indication

- On March 14, 2023, <u>Mirum Pharmaceuticals</u> announced the <u>FDA approval</u> of <u>Livmarli</u> (<u>maralixibat</u>), for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older.
  - Livmarli was previously approved for this indication in patients 1 year of age and older.
- The approval of Livmarli for the expanded indication in patients 3 to < 12 months of age was supported by an open-label study of Livmarli which showed a similar safety, tolerability, and pharmacokinetic profile to patients with ALGS ≥ 12 months of age.
- The recommended dosage of Livmarli is 380 mcg/kg orally once daily, taken 30 minutes before a
  meal in the morning. The starting dosing is 190 mcg/kg administered orally once daily; after one
  week, the dose should be increased to 380 mcg/kg once daily, as tolerated. The maximum daily
  dose volume for patients above 70 kg is 3 mL or 28.5 mg per day.
  - Refer to the dosing by weight guidelines presented in the Livmarli drug label.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.